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ABSTRACT
Background. There is limited literature on patterns of
everolimus use and subsequent hospitalizations and emer-
gency room (ER) visits in real-world clinical practice. In this
study, we describe patterns of everolimus use and hospitali-
zations and ER visits in a large cohort of patients with
breast cancer (BC).
Materials and Methods. Patients with BC treated with
everolimus were identified in the MarketScan database
from 2009 to 2016. The pattern of everolimus use and fre-
quency of associated ER visits and hospitalizations during
treatment (between the first claim and 30 days after the
last claim for everolimus) were identified. Descriptive sta-
tistics and regression models were used.
Results. A total of 3,556 everolimus users were identified
(median age of 60 years; median days of use, 112). The initial
prescribed dose was 10 mg in 74.8% of the patients. Com-
pared with the initial dose, 23.5% of patients had a dose
change. Forty-six percent of patients were hospitalized or
had an ER visit during the treatment with everolimus. Age
greater than 71, higher comorbidity score, treatment year
prior to 2012, and lower initial dose were found to be signifi-
cantly associated with ER visit/hospitalization in the regres-
sion models.
Conclusions. A significant proportion of patients receiving
everolimus had an ER visit or hospitalization during the use of
everolimus. These results provide data regarding risks and ben-
efits of treatment with everolimus. These results will be helpful
in identifying patients at higher risk of hospitalizations or ER
visits and facilitate evidence-based decision making to avoid
serious complications. The Oncologist 2020;25:937–942
Implications for Practice: Everolimus, a mammalian target of rapamycin inhibitor, is approved in combination with exem-
estane in patients with hormone receptor–positive tumors previously treated with anastrozole or letrozole. As new drugs
become available, it is crucial to understand the adverse events and potential complications associated with the use of such
drugs in the general population, outside of the controlled clinical trial setting. This study describes the patterns of
everolimus use and adverse events, including hospitalization and emergency room visits, in a large cohort of patients with
metastatic breast cancer in routine practice.
INTRODUCTION
The number of women living with metastatic breast cancer
(mBC) in the U.S. was estimated to be 138,622 in 2013
[1]. It is projected that the prevalence of mBC will increase
to 168,292 in 2020 [1]. Although mBC is still an incurable
condition, the increasing number of patients living with
mBC is likely due to improved therapies and better survival
[2]. In a contemporary nationally representative cohort, the
5-year breast cancer–specific survival rate for patients diag-
nosed with stage IV de novo was found to be 39% (ranging
from 35% to 43%) [3].
Hormone receptor (HR)–positive and human epidermal
growth factor receptor 2 (HER2)–negative tumors represent
the most common breast cancer subtype, accounting for
close to 70% of all breast cancer cases in the US [4]. The
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goal of treatment for patients with mBC is palliative and focuses
on prolonging life and improving quality of life [1]. Among
patients with metastatic HR-positive and HER2-negative tumors,
endocrine therapy is the cornerstone of treatment [5–8]. Unfor-
tunately, despite initial treatment benefit, almost all patients
develop resistance to endocrine therapy. Targeted therapy with
everolimus, a mammalian target of rapamycin inhibitor, has
been shown to enhance the efficacy of endocrine therapies and
potentially reverse endocrine resistance. In the TAMRAD
study, a phase II clinical trial evaluating the use of tamoxifen
in combination with everolimus versus tamoxifen alone among
patients with HR+/HER2− mBC previously treated with endo-
crine therapy, those receiving the combination had a higher clini-
cal benefit rate (61% vs. 42%, p = .045) and longer time to
progression (8.6 months vs. 4.5 months, p = .002) [9]. The
BOLERO-2 [10] study, a large phase III clinical trial (n = 724),
enrolled postmenopausal women with HR+/HER2− mBC previ-
ously treated with nonsteroidal aromatase inhibitors and ran-
domized them to receive exemestane and everolimus or
exemestane and placebo. Patients receiving everolimus had a
significantly longer progression-free survival compared with
those treated with placebo (7.8 months vs. 3.2 months,
p ≤ .0001). Patients treated in the everolimus arm experi-
enced more adverse events, including stomatitis, fatigue,
nausea, dyspnea, rash, pneumonitis, and anemia [10]
Given the improved outcomes associated with everolimus,
in July 2012, the U.S. Food and Drug Administration (FDA)
approved its use in combination with exemestane for the
treatment of postmenopausal women with advanced HR+
and HER2− that were previously treated with letrozole or
anastrozole [11]. Since then, everolimus has been incorpo-
rated into clinical practice, and its use is supported by
current treatment guidelines [6]. To date, there is limited lit-
erature on patterns of everolimus use and adverse events
associated with its use in real-world clinical practice. In this
study including a large cohort of patients with mBC, we
sought to describe the patterns of everolimus use. In addi-
tion, we describe the rates of hospitalizations and emergency
room (ER) visits that patients experienced while receiving
this therapy.
MATERIALS AND METHODS
Study Design and Data Set
We conducted a retrospective cohort study using the Truven
Health MarketScan Commercial Claims and Encounters data-
base [12]. This large, nationwide employment-based database
includes medical claims data of employees and dependents
from approximately 45 large employers covered by more than
100 payers. The database includes health plans for employees
and dependents receiving insurance through large, medium,
and small-sized firms. For this study, we used claims collected
from 2008 to 2016 to identify individuals who received
everolimus treatment and were diagnosed with breast can-
cer (BC).
Cohort Selection and Definitions
National Drug Code numbers in pharmacy claim files were
used to identify patients who received everolimus
treatment. In total, 7,640 patients were identified
between 2009 and 2016. The date of the first everolimus
claim was used as the index date. Among these patients, a
BC diagnosis was identified by diagnosis codes
(International Classification of Diseases [ICD-9] and ICD-10
174.xx/C50) in one inpatient claim or two outpatient
claims that were more than 30 days apart. Patients with a
BC diagnosis any time before or within 30 days after the
index date were identified as breast cancer cases. The
cohort was then limited by excluding patients aged youn-
ger than 18. Given our intention to study the impact of
comorbidities on the use and adverse events associated
with everolimus, we limited our cohort to individuals with
continuous enrollment during the 6 months before the
index date.
Measures and Outcomes
The baseline characteristics assessed were gender, age, geo-
graphic region (northeast, north central, south, or west), and
insurance type (health maintenance organization [HMO],
preferred provider organization [PPO], or another plan type).
Deyo’s adaptation of Charlson’s comorbidity score [13] was cal-
culated using claims from 6 months before the index date. We
described everolimus treatment patterns, including dose and
duration of treatment, and the endocrine therapies used in
combination with it. We also evaluated chemotherapy adminis-
tration prior to everolimus use. The duration of treatment
was defined as the time from the first claim of everolimus to
the 30th day past the end date of the last everolimus claim.
We evaluated any hospitalization (HSP) and ER visits during the
everolimus treatment as an outcome. We explored the most
common diagnosis codes associated with the HSP/ER. Addi-
tionally, because pneumonitis is a serious known adverse
event, and mucositis or stomatitis is a known concern asso-
ciated with everolimus use, we identified the percentage of
patients that had claims for these two adverse events asso-
ciated with HSP/ER.
Descriptive statistics were used for baseline characteristics.
The time to event was calculated from the index date to the
date of HSP/ER or the last month of enrollment through the
end of the study period, which was December 31, 2016. Multi-
variable Cox regression models were used to determine the
association between patient characteristics and HSP/ER. Dose
modification after the starting dose was modeled as a time-
varying covariate, that is, patients were initially considered
“no change” and then “increased” or “decreased” if their dose
was changed until end of follow-up. Results are expressed in
hazard ratios (HRs) and 95% confidence intervals (CIs). All sta-
tistical analyses were conducted used SAS Enterprise Guide
6 (SAS Institute, Cary, NC) with an a priori significance level of
0.05. The study protocol was determined exempt by the Insti-
tutional Review Board of The University of Texas MD Ander-
son Cancer Center.
RESULTS
Between 2009 and 2016, there were 3,844 patients with
at least one everolimus claim and diagnosis of breast can-
cer, with a total of 3,556 patients meeting our inclusion
and exclusion criteria, as shown in supplemental online
© AlphaMed Press 2020
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Figure 1. Baseline patient and clinical characteristics are
presented in Table 1. The median age of the cohort was
60 years (range, 25–96). Most of the patients (74.8%) had a
comorbidity score of zero and were insured by a PPO plan
(55.3%). A striking increase in everolimus use was identified
from 2012 onward, as expected by the FDA approval of
Table 1. Baseline patient demographics and clinical
characteristics of patients with breast cancer treated with








































Dose change during treatment
No change 2,719 (76.5)
Decrease 600 (16.8)
Increase 237 (6.6)
Abbreviations: HMO, health maintenance organization; PPO, pre-
ferred provider organization.
Table 2. Proportion of adverse events identified during
everolimus treatment (n = 3,556)
Characteristics
HSP/ER (n = 1,623)
n (%) p value
Age, years












Female 1,609 (45.6) .39
Male 14 (53.9)
Geographic region
Northeast 320 (44.6) .03




















Dose change during treatment
No change 1,220 (44.9) .16
Decrease 295 (49.2)
Increase 108 (45.6)
Abbreviations: ER, emergency room; HMO, health maintenance orga-
nization; HSP, hospitalization; PPO, preferred provider organization.
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everolimus for advanced BC in 2012, with a decrease in use
observed in 2015 and 2016.
The median days of everolimus supply was 112 days (inter-
quartile range, 56–196). Although 17.9% of patients had only
one claim for everolimus, 33.3% of patients had six or more
claims. The most common starting dose of everolimus was
10 mg and was used by 74.8% of patients; 19.2% of patients
were initially treated with 5 mg. The majority of patients
(76.5%) did not experience dosing changes during the duration
of their therapy, whereas 16.8% had a dose reduction, and
6.6% had a dose increase. Among those that required a dose
reduction, 89.8% received an initial dose of 10 mg. Exem-
estane was the most commonly coadministered drug used
in 69.4% of patients; anastrozole, tamoxifen, letrozole, and
fulvestrant were coadministered with everolimus in 3.4%,
3.5%, 5.3%, and 0.3% of patients, respectively. No endocrine
therapy was identified in 24% of patients. We also observed
that 59.6% of the patients in our cohort had a claim for che-
motherapy in the year prior to everolimus use.
A total of 1,623 (45.6%) patients had HSP/ER claims dur-
ing everolimus treatment, as shown in Table 2. Of these,
778 (19.8%) had one HSP/ER visit and 845 (25.8%) had
multiple HSP/ER visits. The median time from the initial
everolimus claim to HSP/ER visit was 61 days (interquartile
range, 27–132). The most common diagnosis codes associ-
ated with such visits were hypertension (10.7%), pneumo-
nia (9.7%), pleural effusion (8.3%), dehydration (8.2%), and
shortness of breath (7.1%; supplemental online Table 1).
About 1.1% of the HSP/ER had corresponding diagnosis of
mucositis or stomatitis, and 0.1% of the HSP/ER had a diag-
nosis of pneumonitis.
Table 3 presents the results of multivariable Cox regres-
sion models used to identify patient characteristics associated
with hospitalization or ER visits. Comorbidity index was signifi-
cantly associated with HSP/ER. There was an increased risk of
HSP/ER for patients with a Deyo score of 1 as compared with
0 (HR, 1.25; 95% CI, 1.10–1.43) and for patients with a score
of ≥2 when compared with 0 (H, 1.82; 95% CI, 1.55–2.13).
There was an increased risk of HSP/ER in patients aged 71+
(HR, 1.18; 95% CI, 1.02–1.37) compared with patients aged
25–54. Patients with a lower initial dose (i.e., 2.5 mg) had a
higher risk of HSP/ER when compared with patient with initial
dose of 10 mg (HR, 1.39; 95% CI, 1.05–1.86). The change in
everolimus dose was not associated with HSP/ER. The year of
treatment with everolimus prior to 2012 also showed an
increased risk of HSP/ER as compared with patients being
treated in 2012 (HR, 1.33; 95% CI, 1.02–1.72).
DISCUSSION
In this large study including 3,556 everolimus-treated patients
with mBC, most patients (69.4%) were treated with the com-
bination of everolimus and exemestane, consistent with the
current indication. About half of the patients had a hospitali-
zation or ER visit during everolimus treatment. Age greater
than 71, higher comorbidity score, and lower initial dose
were associated with increased risk of HSP/ER. Interestingly,
we observed there was a trend of fewer HSP/ER in more
recent years, with the percentage decreasing from 58% in
Table 3. Multivariate Cox model results to evaluate the
association between patient characteristics and adverse
outcomes among 3,556 patients with breast cancer treated
with everolimus










































Boldface indicates p < .05.
aTime-dependent covariate.
Abbreviations: CI, confidence interval; ER, emergency room;
HMO, health maintenance organization; HR, hazard ratio; HSP,
hospitalization; PPO, preferred provider organization; Ref.,
reference.
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2009–2011 to 39% in 2016. This decrease may suggest that if
those admissions were related to everolimus toxicities, maybe
the management of adverse events improved over the years,
and those were likely managed in the outpatient setting, pos-
sibly avoiding ER visits or hospitalizations. Two common
adverse effects reported in BOLERO-2 and TAMRAD were sto-
matitis (8% and 56%) and pneumonitis (3% and 17%) in the
treatment arms. These rates contrast with the low rate of sto-
matitis and pneumonitis seen in our study (1.1% and 0.1%). It
is likely that the higher rate of these everolimus-related com-
plications seen in the pivotal trials is related to a higher iden-
tification rate due to the close monitoring of clinical trial
participants. Furthermore, we only report here the percent-
age of patients with a diagnosis of stomatitis and pneumonitis
identified during an ER visit or hospitalization, likely identify-
ing severe cases. Grade 3 or 4 stomatitis and pneumonitis
were reported in 8% and 1% patients in BOLERO-2 trial and
11% and 2% in TAMRAD and are more comparable to the
rates seen in our study.
Guérin et al. [14] reported the treatment patterns
and factors associated with everolimus treatment among
902 postmenopausal women with HR+/HER2− mBC using
the Truven MarketScan and IMS Health PharMetrics data-
bases. Similar to our results, they observed that approxi-
mately 80% of patients initiated everolimus at a dose
of 10 mg daily and noted that less than 5% of patients
experienced a dose increase relative to the index dose,
whereas approximately 20% of patients experienced a
dose reduction. This percentage of patients with dose
reductions is considerably lower than that of BOLERO-2
trial (67%), which could be attributed to the differences in
patient characteristics and study design as well as differences
in management of adverse events in a real-world versus
clinical-trial setting versus the strict protocol-mandated dose
reduction recommendations. Among patients who experi-
enced a dose decrease, the majority initiated a starting dose
of 10 mg daily. Data on toxicities were not reported. In our
results, we report the number of hospitalizations and ER
visits during the treatment with everolimus along with the
most common associated diagnoses.
We observed a relationship between older age, a higher
comorbidity score, and HSP/ER. This finding is not surprising;
it is likely that patients with higher comorbidity index at base-
line were sicker or had worse performance status and there-
fore required an ER visit or hospitalization. Although it is
possible that dose changes occurred as a result of toxicity, we
were unable to determine any such association. Patients
treated with an initial dose of 2.5 mg had an increased risk of
hospitalization or ER compared with patients who received
an initial dose of 10 mg. We cannot exclude that patients
were started at lower doses because of poor overall clinical
condition and thus were more likely to have hospitalization
or ER visits. Given the nature of our claims-based study and
the variables available in the data set, no information on per-
formance status, overall clinical condition, or extent of dis-
ease was available to correlate dose with clinical condition.
The median age in our cohort was 60 years, which is
slightly younger compared with the median age of patients
in the TAMRAD (64) and BOLERO-2 (62) studies. It is unlikely
that our younger patient population accounts for the differ-
ences in the observed adverse events. In our study, patients
aged 71 and older had an increased risk of hospitalization or
ER visits compared with patients aged 25–54.
We also observed the everolimus use decreased in 2015
and 2016, likely due to new alternative treatments approved
for mBC. Cyclin-dependent kinase inhibitor palbociclib was
approved for treatment for mBC in combination with letrozole
in 2015 and in combination with fulvestrant in 2016 [11]. This
decrease in claims for everolimus could also be due to a
decrease in enrollments in the MarketScan data. In 2015,
there was about a 40% decrease in the enrollments in the
MarketScan data because they lost two large health plan data
contributors in their data [12]. We observed some off-label
use of everolimus as we observed claims in 2009–2011, before
the drug was FDA approved for mBC in 2012.
As a retrospective claims-based study, our findings should
be examined considering a few limitations. Performance status
of the patient is an important clinical factor that may impact
treatment decisions and outcomes; however, this information
was not available. It is possible that some of the ER visits or
hospitalizations were due to everolimus toxicity, but given the
limitations of the data, causal etiology cannot be established.
The results of this study highlight the patient experiences
during the treatment in routine practice and thus add to the
evidence on real-world use, outcomes, and quality of care.
Despite these limitations, our study is the first to evaluate hos-
pitalization and ER visits in a large cohort of patients with
mBC treated with everolimus therapy in a real-world clinical
practice. Hospitalization and ER visits have critical impact on
both economic burden and quality of life, including mobility,
functional status, and mental health for patients, and thus it is
important to be characterized.
CONCLUSION
Our results describe patterns of everolimus use and hospi-
talization or ER visits potentially associated with this treat-
ment. The evaluation of HSP/ER over an 8-year period is
another unique feature of our study. As new targeted thera-
pies are incorporated into clinical practice, it is crucial to
describe the adverse events associated with them in the
general population. This much-needed information will pro-
vide providers and patients with accurate data regarding
risks and benefits and will help identify patients at higher
risk of adverse events to avoid serious complications and
facilitate evidence-based decision making.
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